AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
CG Oncology Inc.
Video analysis: CGON
All videosNo video analysis for this stock yet. Request one from our team.
News: CGON
23,000 Shares in CG Oncology, Inc. $CGON Purchased by Jupiter Topco LLC
Jupiter Topco LLC purchased a new stake in shares of CG Oncology, Inc. (NASDAQ: CGON) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,000 shares of the company's stock, valued at approximately $1,634,000. Several other large investors have also recently
15 Stocks to Watch With Short Squeeze Potential
Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.
CG Oncology to Present at Upcoming Investor Conferences in September
DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
CG Oncology: Circling Back After Huge Rally
CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy and best-in-class safety versus competitors. Cret achieved a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C, with no Grade 3+ adverse events. Rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.
CG Oncology, Inc. $CGON Shares Bought by California State Teachers Retirement System
California State Teachers Retirement System increased its stake in CG Oncology, Inc. (NASDAQ: CGON) by 23.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,499 shares of the company's stock after purchasing an additional 9,841 shares during the
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.54 per share a year ago.
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates.
